Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
Editas Medicine Inc(EDIT)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for EDIT
09/16/2026: EDIT (2-star) is a SELL. SELL for 3 days. Simulated Profits (-13.84%). Updated daily EoD!
Editas Medicine is a clinical-stage biotechnology company focused on developing gene-editing medicines using its CRISPR platform. The company's main strength is its early and significant role in establishing the intellectual property landscape for CRISPR technology, which forms the basis for its therapeutic pipeline. Its primary investment story rests on the successful clinical development and eventual approval of lead candidates like reni-cel for blood disorders. However, the company faces high risks, including the absence of commercial revenue, significant cash burn, and intense competition from other well-funded gene-editing firms. Editas best suits growth-oriented investors who can tolerate high volatility, and potential shareholders should monitor upcoming clinical trial results and capital management decisions closely.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-risk, high-reward exposure to the gene-editing sector but lacks a predictable commercial growth trajectory. |
| Momentum investor | Mixed fit | Momentum can be strong during clinical trial updates, but the stock is subject to significant volatility and reversals. |
| Value investor | Weak fit | The company lacks earnings and standard valuation metrics, making it unsuitable for traditional value-based investment approaches. |
| Dividend investor | Weak fit | Editas does not pay a dividend and requires significant capital expenditure for development, precluding income-seeking strategies. |
| Low-risk investor | Weak fit | The binary nature of biotech drug development poses extreme risk and price volatility unsuitable for conservative portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock price is highly sensitive to clinical trial outcomes and biotech sector sentiment. |
| Valuation risk | High | Valuation is speculative and based on the long-term success of early-stage assets. |
| Competition risk (CRISPR/Gene Editing) | High | Well-funded competitors could reach the market sooner or with more effective therapies. |
| Business quality | Medium | While the technology is innovative, the company is still pre-revenue and operationally dependent on future success. |
| Dividend income | Low / none | Investors should not expect income from this equity. |
| Execution risk | High | Successfully managing complex clinical trials and obtaining regulatory approval is difficult and uncertain. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit 5.61% | Avg. Invested days 28 | Today’s Advisory SELL |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 09/16/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 403.92M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 2.5M shares | Beta 2.09 | 52 Weeks Range 1.66 - 4.54 | Updated Date 09/16/2026 |
52 Weeks Range 1.66 - 4.54 | Updated Date 09/16/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.63 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Collaboration and Licensing | Upfront payments, milestone payments, and potential future royalties from partnerships for use of the CRISPR technology platform. | The company generates cash today primarily by licensing its technology to others rather than selling a finished product. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 207.78M | Price to Sales(TTM) 8.59 |
Enterprise Value 207.78M | Price to Sales(TTM) 8.59 | ||
Enterprise Value to Revenue 4.78 | Enterprise Value to EBITDA -1.36 | Shares Outstanding 153.58M | Shares Floating 115.49M |
Shares Outstanding 153.58M | Shares Floating 115.49M | ||
Percent Insiders 0.18 | Percent Institutions 79.19 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Editas Medicine Inc
Exchange NASDAQ | Headquarters Cambridge, MA, United States | ||
IPO Launch date 2016-02-03 | President, CEO & Director Dr. Gilmore O'Neill M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 87 | Website https://www.editasmedicine.com |
Full time employees 87 | Website https://www.editasmedicine.com | ||
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.